PodParley PodParley
PodParley
From the European Hematology Association 2010 Congress: For Patients with Follicular Lymphoma, Rituximab Maintenance Therapy Cuts Risk of Recurrence in Half (Phase III PRIMA Study) episode artwork

EPISODE · Jul 16, 2026 · 8 MIN

From the European Hematology Association 2010 Congress: For Patients with Follicular Lymphoma, Rituximab Maintenance Therapy Cuts Risk of Recurrence in Half (Phase III PRIMA Study)

from Oncology Times - OncTimes Talk

Speaking at the meeting in Barcelona, Gilles Salles of the University of Lyon discusses the results showing that patients who had achieved remissions after immunochemotherapy had only half the risk of recurrence if they also received rituximab maintenance therapy for two years compared with patients who did not.

Episode metadata supplied by the publisher feed · Published Jul 16, 2026

Embed this episode

Ready to play

From the European Hematology Association 2010 Congress: For Patients with Follicular Lymphoma, Rituximab Maintenance Therapy Cuts Risk of Recurrence in Half (Phase III PRIMA Study)

0:00 8:12

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of Oncology Times - OncTimes Talk?

This episode is 8 minutes long.

When was this Oncology Times - OncTimes Talk episode published?

This episode was published on July 16, 2026.

Can I download this Oncology Times - OncTimes Talk episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!